Abstract
PTT.119 [p-F-phe-m-bis(2-chloroethyl)amino-l-phe-met ethoxy HCl], a synthetic tripeptide mustard, was evaluated for therapeutic efficacy against a spectrum of childhood rhabdomyosarcomas (RMS) maintained as xenografts in immune-deprived mice. These xenografts were established from previously untreated tumors, and sublines were selected in mice for resistance to l-phenylalanine mustard (L-PAM). PTT.119 caused regression of four of six RMS lines established from untreated tumors, and demonstrated activity similar to that of L-PAM in this model. Against tumors Rh18/L-PAM and Rh28/L-PAM, selected in situ for L-PAM resistance, PTT.119 had no significant activity. Rh28/L-PAM was cross-resistant also to oxazophosphorine mustards (ifosfamide, cyclophosphamide), and both tumors were cross-resistant to adriamycin and vincristine. PTT.119 caused hematologic toxicity similar to thet of L-PAM, characterized by a marked decrease in white blood cells and thrombocytopenia.
Original language | English (US) |
---|---|
Pages (from-to) | 201-204 |
Number of pages | 4 |
Journal | Cancer chemotherapy and pharmacology |
Volume | 22 |
Issue number | 3 |
DOIs | |
State | Published - Sep 1988 |
Externally published | Yes |
ASJC Scopus subject areas
- Pharmacology (medical)
- Oncology
- Cancer Research
- Toxicology
- Pharmacology